Boehringer Ingelheim Partners with Enleofen to Develop First-in-Class Anti-IL-11 Therapies for a Range of Fibrotic Diseases
9.1.2020 15:00:00 EET | Business Wire | Press release
Boehringer Ingelheim and Enleofen Bio Pte. Ltd. (Enleofen) announced today the acquisition of worldwide exclusive rights to Enleofen’s preclinical interleukin-11 (IL-11) platform by Boehringer Ingelheim to develop first-in-class therapies across a broad range of fibro-inflammatory diseases. The new partnership combines Boehringer Ingelheim’s leading expertise and comprehensive pipeline in fibrotic diseases with Enleofen’s world-leading expertise in IL-11 biology and the company’s extensive range of therapeutic antibodies targeting this pathway.
“The impressive preclinical studies at Enleofen have revealed the potential of IL-11 blockade to treat a broad range of diseases,” said Clive R. Wood, Ph.D., Corporate Senior Vice President and Global Head of Discovery Research at Boehringer Ingelheim. “We are excited to have these monoclonal antibodies in our pipeline and have the opportunity to accelerate their path to many patients whose needs are not met by current treatments.”
IL-11 is a cytokine, a protein certain cells of the body use to communicate, and plays a key role in fibro-inflammatory conditions. Blocking IL-11 action has been shown to inhibit disease across many organs (liver, lung, kidney, retina, bowel, heart and skin). In preclinical studies, antibody-based IL-11 antagonists were able to prevent and reverse inflammation and fibrosis, and restore organ function.
Enleofen is a spin out company from the National Heart Centre Singapore (NHCS) at SingHealth and Duke-NUS Medical School under the SingHealth Duke-NUS Academic Medical Centre (AMC), Singapore and exclusively licensed a suite of patents and number of antibody products when it was founded in 2017, from the AMC. Subsequent to this, Enleofen has built an extensive anti-IL-11 antibody platform and advanced its drug development programs towards the clinic. Boehringer Ingelheim will now develop this platform further and plans to work jointly with scientists at the AMC to accelerate the platform into clinical development. The initial focus will be on novel therapies for patients with NASH and ILDs, two of Boehringer Ingelheim’s core disease focus areas, with a potential to expand into further fibro-inflammatory conditions based on IL-11’s central role in disease.
“Enleofen is very excited to engage Boehringer Ingelheim, a leader in anti-fibrotic therapy R&D to develop further anti-IL-11 therapies to begin to address the unmet medical needs of patients worldwide,” said Prof Stuart Cook, Director and co-founder of Enleofen. “The preclinical data across a range of conditions are unprecedented and this new approach of targeting IL-11 could be a game changer”.
The acquisition of the IL-11 program from Enleofen strengthens Boehringer Ingelheim’s pipeline portfolio, which combines approaches that are effective across multiple fibrotic diseases with disease-specific approaches to achieve greater therapeutic effect and builds on the experience gained with nintedanib in fibrotic lung diseases. Boehringer Ingelheim will be solely responsible for the clinical, regulatory and commercial development of the licensed therapies. Under the terms of the agreement, Enleofen may receive earn out payments in excess of one billion USD per product in upfront and success-based development and commercialization milestones.
For references and notes to editors, please visit:
http://www.boehringer-ingelheim.com/press-release/fibrotic-diseases-partnership-enleofen
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200109005346/en/
Contact information
Boehringer Ingelheim
Dr. Reinhard Malin
Head of Communications Innovation Unit
Boehringer Ingelheim Corporate Center GmbH
Media + PR
P: +49 6132 77-90815
reinhard.malin@boehringer-ingelheim.com
Linda Ruckel
Associate Director, Media and Corporate Reputation
Boehringer Ingelheim U.S.
Media + PR
P: + 203-791-6672
linda.ruckel@boehringer-ingelheim.com
Enleofen
Charu Srivastava
charu@redhill.asia
+65 91810614
Mariyam Haider
mariyam@redhill.asia
+65 86056752
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Fourthline Trust Services Granted Status as Qualified Trust Service Provider in the EU24.8.2026 16:13:00 EEST | Press release
Fourthline Trust Services AB, a subsidiary of Fourthline, has been granted qualified status under the EU's eIDAS Regulation (910/2014)¹ and is now listed on the EU Trusted List as a Qualified Trust Service Provider (QTSP). Supervised by the Swedish Post and Telecom Authority (Post- och telestyrelsen, PTS), Fourthline Trust Services AB issues qualified certificates for electronic signatures. Fourthline, is the leading European provider of AI-powered identity verification (IDV) and compliance solutions. This milestone allows Fourthline full control over the entire digital trust value chain from identity verification to qualified electronic signature (QES) issuance. Ralph Post, Fourthline Trust Services AB Board Member: "By building our QTSP infrastructure similar to our sovereign AI-powered platform that drives our industry-leading identity verification, we're able to offer unprecedented security, performance, and innovation. Organisations can now accelerate their digital transformation
SLB Launches ExaCT Electrical Downhole CT Control System24.8.2026 14:02:00 EEST | Press release
SLB (NYSE: SLB) today launched the ExaCT™ electrical downhole coiled tubing (CT) control system, an advanced intervention platform that introduces real-time electrical control to coiled tubing operations. By replacing pressure-dependent hydraulic actuation with electrical communication, power delivery and telemetry, the ExaCT system gives operators greater visibility, precision and control, helping improve intervention execution and reservoir access. The ExaCT system combines electrical power, telemetry and downhole measurements to enable communication with, actuation of and verification of downhole tools throughout an intervention. Continuous communication across the toolstring enables on-demand tool actuation across a wide range of intervention applications, including extended-reach and multilateral wells. The increased precision and control provided by the system help operators optimize reservoir access, improve production performance and maximize recovery. "Operators are asking int
Wolters Kluwer Transforms Trusted Legal Content Into Structured, AI-Ready Intelligence That Powers the Next Wave of Legal AI24.8.2026 14:01:00 EEST | Press release
Wolters KluwerLegal & Regulatory today announced the next evolution of Libra by Wolters Kluwer, its all-in-one Legal AI Workspace. By transforming authoritative legal sources, expert commentaries, and practical guidance into structured legal intelligence, Wolters Kluwer is making the relationships across the full breadth of its expert legal sources more explicit. This will enable deeper contextual research, more comprehensible answers, and workflow-ready results across legal work. Following the integration of Wolters Kluwer content into the Libra AI workspace in the first half of 2026, laws, rulings, expert commentaries, and practical guidance will now be linked to one another and to the matter at hand, creating a connected knowledge graph of expert-curated and authoredlegal knowledge that AI can reason over. For customers, this means research that surfaces the right authority faster, answers with even clearer reasoning and sources, drafting guided by matter-specific context, and great
Daiichi Sankyo Appoints Markus Kosch to Lead Europe Business as Part of New Commercialization Organization24.8.2026 11:00:00 EEST | Press release
Daiichi Sankyo (TSE: 4568) today announced the appointment of Markus Kosch, MD, as Head of Europe Business, effective April 1, 2027. In this role, he will lead the company's European business within the new globally integrated Commercialization Unit and serve as General Manager of Daiichi Sankyo Europe GmbH, with legal responsibility for the company in Europe. The appointment reflects the next phase of growth of Daiichi Sankyo under its Five-Year Business Plan and the establishment of a new Commercialization Unit. Within this new structure, Markus Kosch will bring together the Oncology and Specialty businesses in Europe under one integrated leadership model to help bring innovative medicines to more patients across the region. For the past five years, Markus Kosch has led the Daiichi Sankyo Oncology Business Division in Europe and Canada, overseeing a period of significant growth and preparing the organization for an increasingly expanding oncology portfolio. Prior to joining Daiichi S
European Commission Approves DAYBU ® (trofinetide) as the First and Only Treatment for Neurobehavioral Symptoms of Rett Syndrome in the European Union24.8.2026 10:01:00 EEST | Press release
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the European Commission (EC) has granted marketing authorization for DAYBU (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older, making it the first and only treatment approved for Rett syndrome in the European Union (EU). “The approval of DAYBU marks a significant milestone for the Rett syndrome community in the EU and advances our mission to bring this innovative treatment to patients and families who have long faced a profound unmet medical need,” said Catherine Owen Adams, Acadia’s Chief Executive Officer. “For people living with Rett syndrome, a devastating rare neurodevelopmental disorder, there have been no approved treatment options in the EU. We are proud to make DAYBU available and look forward to supporting patients, caregivers, and healthcare providers gain access to treatment." The DAYBU marketing authorization in the EU is prim
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom